ALDEYRA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.8 USD | -4.52% |
|
-10.12% | +8.83% |
| Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
| Apr. 03 | Oppenheimer Upgrades Aldeyra Therapeutics to Outperform From Perform, $10 Price Target | MT |
Financials (USD)
| Sales 2024 * | 28.43M | Sales 2025 * | 22.31M | Capitalization | 234M |
|---|---|---|---|---|---|
| Net income 2024 * | -1M | Net income 2025 * | -23M | EV / Sales 2024 * | 8.25 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 10.5 x |
| P/E ratio 2024 * |
-79.6
x | P/E ratio 2025 * |
-10.5
x | Employees | 10 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.24% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aldeyra Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +0.25% | ||
| 1 week | -9.55% | ||
| Current month | +21.71% | ||
| 1 month | +43.17% | ||
| 3 months | +30.92% | ||
| 6 months | +130.06% | ||
| Current year | +13.39% |
1 week
3.83
4.33
1 month
2.764.97
Current year
2.714.97
1 year
1.4211.97
3 years
1.4215.95
5 years
1.4215.95
10 years
1.4216.70
| Managers | Title | Age | Since |
|---|---|---|---|
Todd Brady
CEO | Chief Executive Officer | 52 | 05-08-31 |
Bruce Greenberg
DFI | Director of Finance/CFO | 56 | 19-11-30 |
Caitlin Pazzano
PRN | Corporate Officer/Principal | - | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 58 | 09-04-30 |
Martin Joyce
BRD | Director/Board Member | 70 | 13-09-30 |
Ben Bronstein
BRD | Director/Board Member | 74 | 10-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 3.815 | -4.15% | 245 080 |
| 24-04-18 | 3.98 | +0.25% | 432,657 |
| 24-04-17 | 3.97 | +2.58% | 637,496 |
| 24-04-16 | 3.87 | -6.97% | 725,191 |
| 24-04-15 | 4.16 | -2.12% | 496,422 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Calendar
2024-04-25
- Research & Development Day
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.98
USD
Average target price
9.571
USD
Spread / Average Target
+140.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.39% | 234M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -0.82% | 21.66B | |
| -18.35% | 20.77B | |
| -7.68% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- ALDX Stock
